How to Get Value from a Regulatory Affairs Conference

A week at a regulatory affairs conference costs real money and real time out of the office, and it is easy to come home with a stack of session notes and not much else to show for it. The conferences that pay off are the ones where you treated the agenda as a menu, not a schedule, and spent more of the week talking than listening.

In brief

The sessions are rarely where the value is — the hallway conversation before or after one usually teaches you more than the slide deck did.
A specific question you’re actually stuck on travels farther than “networking” as a goal; it gives the person you’re talking to something concrete to respond to.
An industry conference and an FDA public meeting reward different behavior. FDA’s own public meetings are docketed and procedural under 21 CFR Parts 14 and 15 — a trade conference has none of that structure, and the value model is different.
The trip isn’t over when the flight home lands. The names, ideas, and open questions you collected are only worth something if you follow up on them within a week or two, while the context is still fresh on both ends.

Pick sessions like triage, not a syllabus

A conference agenda is built to look complete, with a session in every slot, and the instinct is to fill your schedule the way you would a course you paid to finish. Treat it more like triage instead. A session is worth your seat if it addresses a question you are actually stuck on, features a speaker you are unlikely to get access to any other way — a working reviewer, a standards committee chair, someone from a company that has already solved the problem you are facing — or covers a topic moving fast enough that you need the update. Everything else is optional, and skipping a mediocre session to keep a good hallway conversation going is a better use of the week, not a worse one. Getting value from a regulatory affairs course is a different problem: a course is built for you to complete start to finish, and skipping around defeats the point. A conference is not built that way, and treating it like one leaves the actual value on the table.

The point is who you end up talking to

Standards working group meetings, chapter meetups, and the meals between sessions are where a conference actually earns its cost, and they work best with a specific, narrow question rather than a general one. “What are people seeing with FDA on X right now” gets a real answer; “tell me about your company” gets a pitch. The relationships a conference starts are the raw material for building a professional network in regulatory affairs over years, not something that gets resolved in a single week — but the week is where most of them start, because it is one of the few times a year the people you would otherwise only email are in the same room.

Where people get stuck

Treating the trip as pure continuing education

Sitting in sessions all day and skipping the parts of the conference that aren’t on the printed agenda gets you a stack of slide decks you could mostly have read on your own time, at a fraction of the cost.

Not writing anything down until you’re back at your desk

A name, a company, and the specific thing you talked about fade within days once you’re back in your normal routine. A one-line note taken the same day is worth more than a detailed memory you are confident you’ll retain.

Never following up

An exchanged card or a LinkedIn connection with no message attached within a couple of weeks is functionally forgotten by the time you need it. The follow-up is what turns a conversation into a relationship.

None of this requires treating a conference like a formal regulatory process — it isn’t one. Getting value from an FDA public meeting means working inside a docketed, procedural structure where the record is the point. A trade conference has no docket and no record; the only thing that carries the value home is what you personally wrote down and who you personally followed up with.

Sources & further reading

21 CFR Part 14 — Public Hearing Before a Public Advisory Committee ecfr.gov
21 CFR Part 15 — Public Hearing Before the Commissioner ecfr.gov
Regulatory Academy — How to Get Value from an FDA Public Meeting regulatoryacademy.com
Regulatory Academy — Building a Professional Network in Regulatory Affairs regulatoryacademy.com
Regulatory Academy — Getting Value from a Regulatory Affairs Course regulatoryacademy.com

This essay is provided for general educational purposes and reflects the regulatory landscape as of its publication date. It is not legal, regulatory, or career advice.